Hepatitis Monthly

Published by: Kowsar

Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia

Ligita Jancoriene 1 , 2 , * , Katazyna Polubenko 2 , Edita Kazenaite 2 , 3 , Arida Buivydiene 2 , 3 , Jolita Jakutiene 3 , Ieva Tolmane 4 , 5 , Agita Jeruma 4 , 6 , Daiva Radzisauskiene 1 , 2 , Evelina Mockiene 2 and Arvydas Ambrozaitis 1 , 2
Authors Information
1 Vilnius University Hospital Santaros Klinikos, Centre of Infectious Diseases, Vilnius, Lithuania
2 Faculty of Medicine, Vilnius University, Vilnius, Lithuania
3 Vilnius University Hospital Santaros Klinikos, Centre of Hepatology, Gastroenterology and Dietetics, Vilnius, Lithuania
4 Riga East University Hospital, Infectology Center of Latvia, Hepatology Department, Riga, Latvia
5 Faculty of Medicine, University of Latvia, Riga, Latvia
6 Riga Stradins University, Department of Infectology and Dermatology, Riga, Latvia
Article information
  • Hepatitis Monthly: January 2018, 18 (1); e62105
  • Published Online: January 14, 2018
  • Article Type: Research Article
  • Received: September 26, 2017
  • Revised: October 28, 2017
  • Accepted: December 31, 2017
  • DOI: 10.5812/hepatmon.62105

To Cite: Jancoriene L, Polubenko K, Kazenaite E, Buivydiene A, Jakutiene J, et al. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia, Hepat Mon. 2018 ; 18(1):e62105. doi: 10.5812/hepatmon.62105.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran. Hepat Mon. 2016;16(4):32654. doi: 10.5812/hepatmon.32654. [PubMed: 27257424].
  • 2. Fattahi MR, Safarpour A, Sepehrimanesh M, Hosseini Asl SM, Mohamaddoust F. The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran. Hepat Mon. 2015;15(2):24734. doi: 10.5812/hepatmon.24734. [PubMed: 25788957].
  • 3. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of hepatitis B and C in patients with hemophilia: A single-centre descriptive study. Shiraz E-Med J. 2015;16(7):24573.
  • 4. World Health Organization . Global report on access to hepatitis C treatment. Focus on overcoming barriers. World Health Organization; 2016.
  • 5. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87. doi: 10.1002/hep.27259. [PubMed: 25069599].
  • 6. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol. 2005;43(4):550-2. doi: 10.1016/j.jhep.2005.07.002. [PubMed: 16099527].
  • 7. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350-9. doi: 10.1136/gut.2005.076646. [PubMed: 16905701].
  • 8. Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, et al. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int. 2015;35(2):510-7. doi: 10.1111/liv.12616. [PubMed: 24905624].
  • 9. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012;54(1):96-104. doi: 10.1093/cid/cir774. [PubMed: 22156853].
  • 10. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014;348:g3308. doi: 10.1136/bmj.g3308. [PubMed: 25002352].
  • 11. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012;366(3):273-5. doi: 10.1056/NEJMe1113272. [PubMed: 22256811].
  • 12. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365 e1. doi: 10.1053/j.gastro.2014.04.045. [PubMed: 24818763].
  • 13. Deeks ED. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs. 2015;75(9):1027-38. doi: 10.1007/s40265-015-0412-z. [PubMed: 26059288].
  • 14. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-603. doi: 10.1056/NEJMoa1315722. [PubMed: 24720703].
  • 15. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64(2):301-7. doi: 10.1016/j.jhep.2015.10.005. [PubMed: 26476290].
  • 16. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-92. doi: 10.1056/NEJMoa1402338. [PubMed: 24795200].
  • 17. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015;49(5):566-81. doi: 10.1177/1060028015570729. [PubMed: 25680759].
  • 18. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-82. doi: 10.1056/NEJMoa1402869. [PubMed: 24725237].
  • 19. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-14. doi: 10.1056/NEJMoa1401561. [PubMed: 24720679].
  • 20. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. [PubMed: 25911336].
  • 21. Lankarani KB, Ardebili M, Sepehrimanesh M, Nejabat M, Hemmati Rad MA, Hosseini SY. Evaluation of hepatitis C virus intrafamilial transmission among families with one index case, a pilot study from Fars province, Iran. Gastroenterol Hepatol Bed Bench. 2016;9(4):250-8. [PubMed: 27895850].
  • 22. Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, Collado Borrell R, Ibanez-Garcia S, et al. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Ann Pharmacother. 2016;50(11):901-8. doi: 10.1177/1060028016659306. [PubMed: 27422641].
  • 23. Chirino-Sprung RA, Dehesa M, Wolpert E, Corona-Lau C, Garcia-Juarez I, Sanchez-Avila JF, et al. Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting. Rev Invest Clin. 2016;68(4):203-12. [PubMed: 27623039].
  • 24. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44(9):946-56. doi: 10.1111/apt.13790. [PubMed: 27611776].
  • 25. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown RJ, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375-82. doi: 10.1056/NEJMoa1408921. [PubMed: 25386767].
  • 26. Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol. 2016;2(2):34-7. doi: 10.5114/ceh.2016.60247. [PubMed: 28856270].
  • 27. Tronina O, Durlik M, Wawrzynowicz-Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L, et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir+/-Ribavirin (OBV/PTV/r/+DSV+/-RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Ann Transplant. 2017;22:199-207. [PubMed: 28386057].
  • 28. Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir+/-dasabuvir+/-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat. 2017;24(11):936-43. doi: 10.1111/jvh.12722. [PubMed: 28480525].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments